SETD2 is frequently mutated in cancer; 4.33% of all cancers carry SETD2 mutations, with endometrial cancer, renal cancer, bladder cancer and colorectal cancer being most frequently associated with SETD2 mutations (reviewed by Fahey and Davis, 2017; Lu et al., 2021). Here, SETD2 is linked to endometrial cancer.